9M 2023 Financial Performance

9M 2023: APPENDIX Cipralex/Lexapro 41 900 600 300 Cipralex/Lexapro revenue (Quarterly DKKm) -19% reported Cipralex escitalopram Lexapro® Cipralex/Lexapro revenue (9M - DKKm) 2,400 1,600 800 -9% reported 0 0 Q3.20 Q3.21 Q3.22 Q3.23 9M 2020 9M 2021 9M 2022 9M 2023 Europe International Markets Unless otherwise stated, growth rates are at CER. 1) Generic launches were seen in 2009-2010 in countries such as Australia, Brazil, Canada, Finland, Norway and Spain as a consequence of different patent extension rules at the time. RoW: Rest of World Comments . • Down 5% (-9% reported) reaching DKK 1.7bn in 9M 2023 The biggest markets are China, South Korea, Brazil, Italy and Japan in 9M 2023 The patent expired in 2012 (U.S.) and in 2014 (most of RoW)¹) Market exclusivity in Japan expired April 2021

View entire presentation